会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明授权
    • Process for the preparation of water soluble primycin and its components
and pharmaceutical compositions containing them
    • 制备水溶性伯霉素及其组分和含有它们的药物组合物的方法
    • US5441940A
    • 1995-08-15
    • US133795
    • 1993-10-08
    • Tamas KeresztesAndras KoverGabor KulcsarKatalin ErdodineGergelyne P. Katalin
    • Tamas KeresztesAndras KoverGabor KulcsarKatalin ErdodineGergelyne P. Katalin
    • A61K31/70A61K31/7042A61K31/7048A61P31/04C07H17/08C07H15/04
    • C07H17/08
    • The invention relates to a process for the preparation of water soluble primycin and to the separation of its components of formulae (A.sub.1) and (A.sub.3) either as single components or as a mixture of the two components. According to the invention(i) water insoluble primycin is reacted in a C.sub.1-3 alcohol with a condensable substance comprising a C--C--C bridge in the presence of sodium or potassium methoxide or ethoxide, the resulting product with a water solubility of 40-60 mg/ml is separated, and, if desired,(ii) the resulting substance is subjected to column chromatography on silica gel applying a 1% aqueous solution of Partridge mixture as eluting agent to obtain a mixture of components of formulae (A.sub.1) and (A.sub.3) with a water solubility of 50 mg/ml, and, if desired,(iii) the resulting two-component mixture is subjected to ion exchange chromatography applying carboxymethyl cellulose in ammonium cycle as adsorbent and eluting the adsorbent with aqueous ammonium hydrocarbonate solution to obtain the component of formula (A.sub.3) with a water solubility of 50 mg/ml in pure form, and, if desired,(iv) elution is continued with absolute methanol comprising 10 mmoles of acetic acid to obtain the component of formula (A.sub.1) with a water solubility of 10 mg/ml in pure form.
    • 本发明涉及一种用于制备水溶性伯霉素的方法,以及将其式(A1)和(A3)的组分分离为单一组分或作为两种组分的混合物。 根据本发明(i)水溶性伯霉素在甲醇钠或乙醇钠或甲醇钾存在下,在C 1-3醇与包含CCC桥的可冷凝物质反应,所得产物的水溶解度为40-60mg / ml,并且如果需要,(ii)将得到的物质在硅胶上进行柱色谱,用1%的鹧鸪混合物水溶液作为洗脱剂,得到式(A1)和(A3)的组分的混合物, 水溶解度为50mg / ml,如果需要,(iii)将得到的双组分混合物进行离子交换色谱,在铵循环中用羧甲基纤维素作为吸附剂,并用碳酸氢铵水溶液洗脱该吸附剂,得到 水溶性为纯净形式为50mg / ml的式(A3)组分,如果需要,(iv)用包含10mmol乙酸的无水甲醇继续洗脱,得到f (A1),水溶性为10mg / ml,纯净。
    • 8. 发明授权
    • Hermetic pump module for double cladding fiber amplifiers and method for making same
    • 双包层光纤放大器的密封泵模块及其制造方法
    • US06717720B2
    • 2004-04-06
    • US09994788
    • 2001-11-28
    • Lew GoldbergMarc LeFlohicGabor Kulcsar
    • Lew GoldbergMarc LeFlohicGabor Kulcsar
    • H01S300
    • H01S3/094003G02B6/4214G02B6/4248H01S3/06704H01S3/094007H01S3/094019H01S3/0941
    • An apparatus and method of hermetically sealing a pump module for a double cladded fiber in a pump module. The apparatus includes a hermetic pump module for coupling light from a pump source into an optical waveguide. The hermetic pump module includes a hermetically sealed housing, wherein the hermetically sealed housing contains an all-glass double cladded fiber with an outer cladding, an inner cladding, and a core, wherein the double cladded fiber includes a v-groove that extends through the outer cladding into the inner cladding, a pump source that emits a light, and a transparent substrate, bonded to the glass outer cladding with a transparent adhesive, wherein the light passes through the transparent substrate and into the all-glass double cladded fiber and the v-groove couples the light into the all-glass double cladded fiber. Alternatively, the substrate may be eliminated and the light directly coupled into the all-glass double cladded fiber.
    • 一种在泵模块中密封双层包覆纤维的泵模块的装置和方法。 该装置包括用于将来自泵浦源的光耦合到光波导中的密封泵模块。 密封泵模块包括气密密封的壳体,其中密封的壳体包含具有外包层,内包层和芯的全玻璃双包层光纤,其中双包层光纤包括延伸穿过 外包层,发射光的泵浦源和透明基板,透明粘合剂结合到玻璃外包层,其中光穿过透明基板并进入全玻璃双包层光纤,并且 v型槽将光线连接到全玻璃双层包覆纤维中。 或者,可以去除衬底,并且将光直接耦合到全玻璃双包层光纤中。
    • 9. 发明授权
    • Process for the preparation of quinoline-carboxylic acid derivatives
    • 喹啉羧酸衍生物的制备方法
    • US4935512A
    • 1990-06-19
    • US273853
    • 1988-06-03
    • Judit FrankKlara Beres nee PalmaiGabor Kulcsar
    • Judit FrankKlara Beres nee PalmaiGabor Kulcsar
    • A61K31/495A61P31/04C07D215/56C07D215/58
    • C07D215/56
    • The invention relates to a new and simple process for the preparation of quinoline-carboxylic acid derivatives of the general formula (I) ##STR1## as well as hydrates and therapeutically acceptable salts thereof. In the formula the meaning of the substituents is as follows:R is hydrogen atom or a formyl group,R.sup.1 is a hydrogen atom or a straight or branched chain alkyl group having 1 to 4 carbon atoms, which may be substituted by a hydroxyl group, a halogen atom or an amino group; or a CH.sub.3 --NH-group,R.sup.2 is a hydrogen atom or an alkyl group having 1 to 4 carbon atoms.According to the invention the compound of the general formula (II) ##STR2## or an acid addition salt thereof is reacted with piperazine in dimethylformamide and--if desired--the compound of the general formula (III) ##STR3## thus obtained is subjected to an acidic or alkaline treatment, or is reacted advantageously with hydrazine or preferably with hydrazine-hydrate.
    • PCT No.PCT / HU87 / 00044 Sec。 371日期:1988年6月3日 102(e)日期1988年6月3日PCT提交1987年10月14日PCT公布。 出版物WO88 / 02748 日本时间1988年04月21日。本发明涉及一种制备通式(I)的喹啉羧酸衍生物的新的和简单的方法,其水合物及其可治疗的盐。 在该式中,取代基的含义如下:R是氢原子或甲酰基,R 1是氢原子或可被羟基取代的具有1至4个碳原子的直链或支链烷基, 卤原子或氨基; 或CH 3 -NH基,R 2为氢原子或碳原子数1〜4的烷基。 根据本发明,通式(II)的化合物或其酸加成盐与二甲基甲酰胺中的哌嗪反应,如果需要,将通式(III)的化合物(III) )进行酸性或碱性处理,或有利地与肼反应或优选与肼水合物反应。
    • 10. 发明授权
    • Synergistic antimicrobial compositions
    • 协同抗菌组合物
    • US4404189A
    • 1983-09-13
    • US226615
    • 1981-01-21
    • Gabor KulcsarGyula SebestyenAgoston DavidTibor Zilahi
    • Gabor KulcsarGyula SebestyenAgoston DavidTibor Zilahi
    • A61K31/65A61K35/00
    • A61K31/70A61K31/65
    • A synergistic antimicrobial active ingredient for a pharmaceutical or veterinary composition comprises 5 to 50 percent by weight of a primycin component which consists of a primycin fermentation product of Thermonospora galeriensis and 95 to 50 percent by weight of at least one other component selected from the group which consists of doxycyline compounds and sisomicin compounds. The doxycycline compounds are selected from the group which consists of doxycycline, salts thereof with mineral acids, and doxycycline tryclate. The sisomicin compounds are selected from the group which consists of sisomicin, substituted sisomicins with substitution at the N atom by lower alkyl, hydroxyl lower alkyl, lower aminoalkyl and lower alkanoyl, and sisomicin acid salts.
    • 用于药物或兽医组合物的协同抗微生物活性成分包含5-50重量%的伯霉素组分,所述伯霉素组分由热霉菌属(Thermomonospora galeriensis)的伯霉素发酵产物和95至50重量%的至少一种选自以下的组中 由多西环素化合物和西索米星化合物组成。 多西环素化合物选自由多西环素,其与无机酸的盐和多西环素三环酸组成的组。 西索米星化合物选自西索霉素,在N原子被低级烷基取代的取代的西索米星,羟基低级烷基,低级氨基烷基和低级烷酰基以及西索米星酸盐组成的组。